Table 1 Sociodemographic and clinical characteristics of the study population (n = 34).
Variables | Valproic acid group (n = 17) N (%) | Placebo group (n = 17) N (%) | p value# |
|---|---|---|---|
Sex | 1.000 | ||
Male | 16 (94.1) | 17 (100) | |
Female | 1 (5.9) | 0 (0) | |
Ethnicity | 0.492 | ||
Caucasian | 8 (47) | 10 (58.9) | |
Non-Caucasian | 9 (53) | 7 (41.1) | |
Previously treated primary tumor location | 0.283 | ||
Oral cavity | 7 (41.1) | 2 (11.8) | |
Oropharynx | 3 (17.7) | 5 (29.4) | |
Larynx | 5 (29.4) | 6 (35.3) | |
Hypopharynx | 2 (11.8) | 4 (23.5) | |
ECOG | 1.000 | ||
1 | 13 (76.4) | 14 (82.3) | |
2 | 4 (23.6) | 3 (17.7) | |
Tobacco status | 0.714 | ||
Active smoker | 6 (35.3) | 5 (29.4) | |
Former smoker | 11 (64.7) | 12 (70.6) | |
Comorbidities | 1.000 | ||
Absent | 15 (88.2) | 16 (94.1) | |
Present | 2 (11.8) | 1 (5.9) |
